Pennant Investors’s Novavax NVAX Stock Holding History

Pennant Investors’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-60,300	Closed	-$763K	–	36
2024 Q2	$763K	Hold	60,300	–	–	0.2%	18
2024 Q1	$288K	Hold	60,300	–	–	0.07%	35
2023 Q4	$289K	Buy	+60,300	New	+$369K	0.06%	38

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Pennant Investors's NVAX Position: Q3 2024 in Review

Pennant Investors sold out of Novavax (NVAX) in Q3 2024, closing a stake of 60,300 shares — an estimated $763K sold.

Pennant Investors first reported a position in NVAX in Q4 2023 and held it in 3 quarters. The position peaked at $763K in Q2 2024. 237 funds tracked by Wall St. Rank hold NVAX as of Q3 2024.

Pennant Investors reported no remaining Novavax position as of Q3 2024 after selling out during the quarter.
Pennant Investors sold 60,300 Novavax shares in Q3 2024, an estimated $763K.
Pennant Investors first reported a position in Novavax in Q4 2023 and held it in 3 quarters.
Pennant Investors's Novavax position peaked at $763K in Q2 2024.
237 funds tracked by Wall St. Rank held Novavax as of Q3 2024.

Based on Pennant Investors's 13F filing for Q3 2024, filed 14 Nov 2024.